Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | DHODH | Q02127 | 3/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27945291 | 0.98 | PARP1 (0.74) | PARP1ALDH1A1DHODHNR4A1NR4A2 | |
| SCHEMBL3151445 | 0.89 | PARP1 (0.61) | PARP1ALDH1A1DHODHNR4A1NR4A2 | |
| SCHEMBL1033354 | 0.87 | PARP1 (0.60) | PARP1ALDH1A1DHODHLMNAALOX12 | |
| SCHEMBL6442515 | 0.87 | PARP1 (1.00) | PARP1ALDH1A1DHODHKDM4EMEN1 | |
| SCHEMBL31061508 | 0.87 | PARP1 (1.00) | PARP1ALDH1A1DHODHKDM4EMEN1 | |
| SCHEMBL28609706 | 0.84 | PARP1 (0.57) | PARP1DHODHLMNAKDM4E | |
| SCHEMBL1076631 | 0.84 | PARP1 (0.56) | PARP1ALDH1A1KDM4ETP53 | |
| SCHEMBL15228833 | 0.83 | PARP1 (0.67) | PARP1ALDH1A1KDM4EMEN1RAB9A | |
| SCHEMBL1035548 | 0.82 | PARP1 (0.65) | PARP1ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL1032405 | 0.81 | PARP1 (0.53) | PARP1ALDH1A1DHODHPDE10ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| CN-103360414-A | Quinoline rare earth complex, catalyst and polymerization method | QINGDAO YIKESI NEW MATERIAL CO LTD | 2013-10-23 | — | — | CN | disclosed |
| CN-102050839-B | Coordination compound for catalyzing vinyl polymerization and preparation method of coordination compound as well as catalyst containing coordination compound and application of catalyst | CHINESE ACAD INST CHEMISTRY | 2012-07-04 | — | — | CN | disclosed |
| CN-102050839-A | Coordination compound for catalyzing vinyl polymerization and preparation method of coordination compound as well as catalyst containing coordination compound and application of catalyst | CHINESE ACAD INST CHEMISTRY | 2011-05-11 | — | — | CN | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| CN-101541751-A | Quinoline compounds | WYETH CORP (US) | 2009-09-23 | — | — | CN | disclosed |
| WO-2005118580-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF THE HYPOXIC SIGNALING PATHWAY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-0206802-B1 | SUBSTITUTED QUINOLINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-09-01 | — | — | EP | disclosed |
| US-4904659-A | Substituted quinoline derivatives and pharmaceutical compositions thereof | DEVELOPMENT FINANCE CORPORATION OF NEW ZELAND (NZ) | 1990-02-27 | — | — | US | disclosed |
| EP-0206802-A2 | Substituted quinoline derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PARP1 183/4885ALDH1A1 2326/4885DHODH 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.